About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
Investors
Contact us
News
ASX Releases
Bioshares Summit 2022 Presentation
May 12, 2022
Read more
Read more
RAD Licenses UCLA Dual Action Antibody
April 4, 2022
Read more
Read more
RAD Dual Action Antibody Investor Deck
April 4, 2022
Read more
Read more
Radiopharm Theranostics Investor Presentation
March 28, 2022
Read more
Read more
Radiopharm signs LOI with GenesisCare to start first trial in Australia
March 23, 2022
Read more
Read more
Hester Larkin appointed as Non-Executive Director
February 2, 2022
Read more
Read more
Radiopharm and TerraPower sign supply agreement for Actinium-225
February 1, 2022
Read more
Read more
RAD Acquires IP ownership of Radiopharmaceutical Nanobodies
January 24, 2022
Read more
Read more
RAD to present at Biotech Showcase
January 10, 2022
Read more
Read more
Radiopharm Expands Management Team with Three Senior Appointments
December 20, 2021
Read more
Read more
Completion of Phase 1 Study in Breast Cancer
December 17, 2021
Read more
Read more
Letter to Shareholders
December 10, 2021
Read more
Read more
RAD's Integrins Technology featured in Cancers Journal
December 8, 2021
Read more
Read more
Dr Hurvitz SAB Appointment
December 6, 2021
Read more
Read more
ASX Investor Presentation 29 Nov 2021
November 29, 2021
Read more
Read more
Radiopharm Theranostics Lists on the ASX After Raising $50M in IPO
November 25, 2021
Read more
Read more
Radiopharm Theranostics’ Trivehexin (AVβ6-Integrin) published in European Journal of Nuclear Medicine
October 13, 2021
Read more
Read more
European Molecular Imaging Meeting (EMIM) RAD301 Abstract
September 21, 2021
Read more
Read more
RAD201 Published in peer reviewed Journal Molecular Pharmaceutics
September 15, 2021
Read more
Read more
Radiopharm raise release FINAL
August 23, 2021
Read more
Read more
RadioPharm and TRIMT
August 17, 2021
Read more
Read more
MEDIA releases
Radiopharm Theranostics panel discusses latest progress and understanding of the radiopharmaceutical sector
May 9, 2022
Read more
Read more
Radiopharm continues strong progress and recognition of AVβ6-Integrin in Europe
May 6, 2022
Read more
Read more
CEO Riccardo Canevari visits Sydney and discusses the use of radiopharmaceuticals with Financial News Network
April 4, 2022
Read more
Read more
Appointment of Bill Regan to Senior Vice President Regulatory Strategy
March 15, 2022
Read more
Read more
Presentation at Financial News Network Investor Conference Feb 2022
February 24, 2022
Read more
Read more
Paul Hopper speaks to Matt Birney from Bulls N' Bears
February 18, 2022
Read more
Read more
RAD Expands Management Team with VP of Clinical Development Appointed
February 17, 2022
Read more
Read more
Acceleration in Patient Recruitment with AVB6 - Integrin
February 11, 2022
Read more
Read more
Bulls N' Bears Interview
November 29, 2021
Read more
Read more
Radiopharm Theranostics makes its debut on the ASX as it develops its cancer killing technology
November 25, 2021
Read more
Read more
Radiopharm Theranostics’ Founder Paul Hopper’s keynote address at Emerging Small Caps 2021 Summit
November 12, 2021
Read more
Read more
Paul Hopper’s Radiopharm, Artrya pitch investors this week
October 11, 2021
Read more
Read more
Entrepreneur Paul Hopper launches Radiopharm Theranostics following AU$20M Series A
September 17, 2021
Read more
Read more
Radiopharm secures ex Novartis exec as CEO ahead of IPO
September 6, 2021
Read more
Read more
Biotech veteran Paul Hopper taps Bell Potter and Baker Young for Radiopharma Theranostics pre-IPO
August 23, 2021
Read more
Read more
Sign up to our mailing list.
Receive all the latest news from Radiopharm Theranostics.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please fill out all starred fields.